Are companion diagnostics useful?

Clinical Chemistry

Volumn 59, Issue 1, 2013, Pages 198-201

  Barrett, J Carl ^a   Frigault, Melanie M ^a   Hollingsworth, Simon ^a   Miller, Glenn A ^a   Modur, Vijay ^b  

^a ASTRAZENECA   (United Kingdom)

^b HTG Molecular Diagnostics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BCR ABL PROTEIN; CETUXIMAB; CRIZOTINIB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; HOMOHARRINGTONINE; IMATINIB; K RAS PROTEIN; NILOTINIB; PANITUMUMAB; TRASTUZUMAB; VEMURAFENIB;

BREAST CANCER; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; COMPANION DIAGNOSTIC TEST; DIAGNOSTIC TEST; FOOD AND DRUG ADMINISTRATION; GENE AMPLIFICATION; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; MOLECULARLY TARGETED THERAPY; NOTE; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; SEQUENCE ANALYSIS;

EID: 84872017234     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.185132     Document Type: Note

References (17)

1. Arteaga CL, Baselga J. Impact of genomics on personalized cancer medicine. Clin Cancer Res 2012;18:612-8.
2. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010;363:301-4.
3. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011;12:1004 -12.
4. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14.
5. Saltz L. Epidermal growth factor receptornegative colorectal cancer: Is there truly such an entity? Clin Colorectal Cancer 2005;5(Suppl 2): S98-100.
6. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
7. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
8. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
9. Lindström LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012;30:2601-8.
10. Garraway LA, Janne PA. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2012;2:214-26.
11. Hockett RD, Close SL. Regulation of laboratorydeveloped tests: the case for utilizing professional associations. Clin Pharmacol Ther 2010;88:743-5.
12. Hirsch FR, Wynes MW, Gandara DR, Bunn PA Jr. The tissue is the issue: personalized medicine for non-small cell lung cancer. Clin Cancer Res 2010;16:4909-11.
13. Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012;2:82-93.
14. Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JM. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 2004;10:4793-8. (Pubitemid 38955532)
15. Garraway LA. Concordance and discordance in tumor genomic profiling. J Clin Oncol 2012;30:2937-9.
16. White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Lynn Wang Y, et al. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood 2010;116:e111-7.
17. Institute of Medicine. Evolution of translational omics: lessons learned and the path forward. Micheel CM, Nass SJ, Omenn GS, eds. Washington (DC): National Academies Press; 2012.